GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensysce Biosciences Inc (NAS:ENSC) » Definitions » Selling, General, & Admin. Expense

Ensysce Biosciences (Ensysce Biosciences) Selling, General, & Admin. Expense : $5.18 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ensysce Biosciences Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Ensysce Biosciences's selling, general, & admin. expense for the three months ended in Mar. 2024 was $1.37 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $5.18 Mil.


Ensysce Biosciences Selling, General, & Admin. Expense Historical Data

The historical data trend for Ensysce Biosciences's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensysce Biosciences Selling, General, & Admin. Expense Chart

Ensysce Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
1.16 18.71 6.91 5.36

Ensysce Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.56 1.14 1.23 1.44 1.37

Competitive Comparison of Ensysce Biosciences's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Ensysce Biosciences's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensysce Biosciences's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Ensysce Biosciences's Selling, General, & Admin. Expense falls into.



Ensysce Biosciences Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ensysce Biosciences  (NAS:ENSC) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Ensysce Biosciences Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Ensysce Biosciences's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensysce Biosciences (Ensysce Biosciences) Business Description

Industry
Traded in Other Exchanges
N/A
Address
7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.
Executives
Bob G Gower director 402 TIMBERWILDE LANE, HOUSTON TX 77024
Lynn Kirkpatrick director, officer: Chief Executive Officer 110 110TH AVENUE NE, SUITE 685, BELLEVUE WA 98004
Nilab Osman officer: Chief Medical Officer C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Lee M. Rauch director C/O ENSYSCE BIOSCIENCES, INC., 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Linda Pestano officer: Chief Development Officer 7946 IVANHOE AVENUE, LA JOLLA CA 92037
Kevin Geoffrey Birkett officer: Chief Commercial Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
William K Schmidt officer: Chief Medical Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
David Carl Humphrey officer: Chief Financial Officer 4767 NEXUS CENTRE DR, SAN DIEGO CA 92121
William H Chang director, 10 percent owner C/O SEMLER SCIENTIFIC, INC., 911 BERN COURT, SUITE 110, SAN JOSE CA 95112
Andrew Benton director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Adam Levin director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Jeffrey Millard officer: Chief Operating Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Richard Chester Wright officer: Chief Business Officer 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037
Steven Robert Martin director 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Curtis Rosebraugh director 7946 IVANHOE AVENUE, SUITE 201, LA JOLLA CA 92037